Pathogenesis of chronic active Epstein-Barr virus infection: Is this an infectious disease, lymphoproliferative disorder, or immunodeficiency?

Reviews in Medical Virology

Volumn 16, Issue 4, 2006, Pages 251-261

  Kimura, Hiroshi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; CARRIER PROTEIN; CYCLOSPORIN A; ETOPOSIDE; GANCICLOVIR; IMMUNOMODULATING AGENT; INTERLEUKIN 2; PROTEIN EBNA1; PROTEIN LMP1; PROTEIN LMP2; STEROID; UNCLASSIFIED DRUG; VIDARABINE; VIRUS ANTIGEN;

ALLOGENEIC STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; DRUG TOLERANCE; EPSTEIN BARR VIRUS; FEVER; GENE EXPRESSION; HEPATITIS; HEPATOSPLENOMEGALY; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; INFECTION; LYMPHOPROLIFERATIVE DISEASE; METHYLATION; MORBIDITY; MORTALITY; NASOPHARYNX CARCINOMA; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; RARE DISEASE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPLENOMEGALY; SYMPTOM; T CELL LYMPHOMA; VIRUS INFECTION;

EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; INFECTIOUS MONONUCLEOSIS; KILLER CELLS, NATURAL; LYMPHOPROLIFERATIVE DISORDERS; T-LYMPHOCYTES;

EID: 33746562435     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.505     Document Type: Review

References (100)

1. Rickinson AB, Kieff E. Epstein-Barr Virus. In Virology (4th edn, Vol. 2), Knipe DM, Howly PM (eds). Lippincott Williams & Wilkins: Philadelphia, 2001; 2575-2627.
2. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-492.
3. Virelizier JL, Lenoir G, Griscelli C. Persistent Epstein-Barr virus infection in a child with hypergammaglobulinaemia and immunoblastic proliferation associated with a selective defect in immune interferon secretion. Lancet 1978; 2: 231-234.
4. Tobi M, Morag A, Ravid Z, et al. Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection. Lancet 1982; 1: 61-64.
5. Jones JF, Ray CG, Minnich LL, Hicks MJ, Kibler R, Lucas DO. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med 1985; 102: 1-7.
6. Tobi M, Straus SE. Chronic Epstein-Barr virus disease: a workshop held by the National Institute of Allergy and Infectious Diseases. Ann Intern Med 1985; 103: 951-953.
7. Straus SE, Tosato G, Armstrong G, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 1985; 102: 7-16.
8. Alfieri C, Ghibu F, Joncas JH. Lytic, nontransforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection. Can Med Assoc J 1984; 131: 1249-1252.
9. Schooley RT. Chronic fatigue syndrome: a manifestation of Epstein-Barr virus infection? Curr Clin Top Infect Dis 1988; 9: 126-146.
10. Straus SE, Cohen JI, Tosato G, Meier J. NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 1993; 118: 45-58.
11. Rickinson AB. Chronic, symptomatic Epstein-Barr virus infection. Immunol Today 1986; 7: 13-14.
12. Straus SE. The chronic mononucleosis syndrome. J Infect Dis 1988; 157: 405-412.
13. Okano M, Matsumoto S, Osato T, Sakiyama Y, Thiele GM, Purtilo DT. Severe chronic active Epstein-Barr virus infection syndrome. Clin Microbiol Rev 1991; 4: 129-135.
14. Yamamoto M, Kimura H, Hironaka T, et al. Detection and quantification of virus DNA in plasma of patients with Epstein-Barr virus-associated diseases. J Clin Microbiol 1995; 33: 1765-1768.
15. Kanegane H, Wakiguchi H, Kanegane C, Kurashige T, Miyawaki T, Tosato G. Increased cell-free viral DNA in fatal cases of chronic active Epstein- Barr virus infection. Clin Infect Dis 1999; 28: 906-909.
16. Maeda A, Wakiguchi H, Yokoyama W, Hisakawa H, Tomoda T, Kurashige T. Persistently high Epstein-Barr virus (EBV) loads in peripheral blood lymphocytes from patients with chronic active EBV infection. J Infect Dis 1999; 179: 1012-1015.
17. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001; 98: 280-286.
18. Jones J, Shurin S, Abramowsky C, et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med 1988; 318: 733-741.
19. Kikuta H, Taguchi Y, Tomizawa K, et al. Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature 1988; 333: 455-457.
20. Kawa-Ha K, Ishihara S, Ninomiya T, et al. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest 1989; 84: 51-55.
21. Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 2003; 187: 527-533.
22. Schooley RT, Carey RW, Miller G, et al. Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy. Ann Intern Med 1986; 104: 636-643.
23. Ohga S, Takada H, Honda K, et al. Central nervous system T-cell lymphoproliferative disorder in a patient with chronic active Epstein-Barr virus infection. J Pediatr Hematol Oncol 1999; 21: 42-46.
24. Tosato G, Straus S, Henle W, Pike SE, Blaese RM. Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis). J Immunol 1985; 134: 3082-3088.
25. Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999; 37: 132-136.
26. Ishihara S, Okada S, Wakiguchi H, Kurashige T, Hirai K, Kawa-Ha K. Clonal lymphoproliferation following chronic active Epstein-Barr virus infection and hypersensitivity to mosquito bites. Am J Hematol 1997; 54: 276-281.
27. Iwatsuki K, Xu Z, Takata M, et al. The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol 1999; 140: 715-721.
28. Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 2005; 80: 64-69.
29. +-activated T cells in primary EBV infection. J Immunol 1999; 163: 5735-5740.
30. Jager M, Prang N, Mitterer M, et al. Pathogenesis of chronic Epstein-Barr virus infection: detection of a virus strain with a high rate of lytic replication. Br J Haemat 1996; 95: 626-636.
31. Kawa-Ha K, Tanaka K, Inoue M, et al. Isolation of human herpesvirus 7 from a child with symptoms mimicking chronic Epstein-Barr virus infection. Br J Haematol 1993; 84: 545-548.
32. Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol 2004; 78: 5194-5204.
33. Imai S, Sugiura M, Oikawa O, et al. Epstein-Barr virus (EBV)-carrying and -expressing T-cell lines established from severe chronic active EBV infection. Blood 1996; 87: 1446-1457.
34. Yoshioka M, Ishiguro N, Ishiko H, Ma X, Kikuta H, Kobayashi K. Heterogeneous, restricted patterns of Epstein-Barr virus (EBV) latent gene expression in patients with chronic active EBV infection. J Gen Virol 2001; 82: 2385-2392.
35. Kimura H, Hoshino Y, Hara S, et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. J Infect Dis 2005; 191: 531-539.
36. Yoshioka M, Kikuta H, Ishiguro N, Ma X, Kobayashi K. Unique Epstein-Barr virus (EBV) latent gene expression, EBNA promoter usage and EBNA promoter methylation status in chronic active EBV infection. J Gen Virol 2003; 84: 1133-1140.
37. Ohshima K, Suzumiya J, Ohga S, Ohgami A, Kikuchi M. Integrated Epstein-Barr virus (EBV) and chromosomal abnormality in chronic active EBV infection. Int J Cancer 1997; 71: 943-947.
38. Kikuta H, Nakanishi M, Sakiyama Y, Matsumoto S. Chronic active Epstein-Barr virus (EBV) infection is associated with clonotypic intracellular terminal regions of the EBV. J Infect Dis 1989; 160: 546-547.
39. Quintanilla-Martinez L, Kumar S, Fend F, et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood 2000; 96: 443-451.
40. Kawa K. Epstein-Barr virus-associated diseases in humans. Int J Hematol 2000; 71: 108-117.
41. Kanegane H, Wado T, Nunogami K, Seki H, Taniguchi N, Tosato G. Chronic persistent Epstein-Barr virus infection of natural killer cells and B cells associated with granular lymphocytes expansion. Br J Haematol 1996; 95: 116-122.
42. Kasahara Y, Yachie A. Cell type specific infection of Epstein-Barr virus (EBV) in EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Crit Rev Oncol Hematol 2002; 44: 283-294.
43. Toyabe S, Harada W, Uchiyama M. Biclonal expansion of T cells infected with monoclonal Epstein-Barr virus (EBV) in a patient with chronic, active EBV infection. Clin Exp Immunol 2003; 134: 92-97.
44. Endo R, Yoshioka M, Ebihara T, Ishiguro N, Kikuta H, Kobayashi K. Clonal expansion of multiphenotypic Epstein-Barr virus-infected lymphocytes in chronic active Epstein-Barr virus infection. Med Hypotheses 2004; 63: 582-587.
45. Kanegane H, Bhatia K, Gutierrez M, et al. A syndrome of peripheral blood T-cell infection with Epstein-Barr virus (EBV) followed by EBV-positive T-cell lymphoma. Blood 1998; 91: 2085-2091.
46. Kawa K, Okamura T, Yagi K, Takeuchi M, Nakayama M, Inoue M. Mosquito allergy and Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease. Blood 2001; 98: 3173-3174.
47. Kasahara Y, Yachie A, Takei K, et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 2001; 98: 1882-1888.
48. Tsuge I, Morishima T, Morita M, Kimura H, Kuzushima K, Matsuoka H. Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line. Clin Exp Immunol 1999; 115: 385-392.
49. Imadome K, Shimizu N, Arai A, et al. Coexpression of CD40 and CD40 ligand in Epstein-Barr virus-infected T and NK cells and their role in cell survi-val. J Infect Dis 2005; 192: 1340-1348.
50. Imadome K, Shirakata M, Shimizu N, Nonoyama S, Yamanashi Y. CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation. Proc Natl Acad Sci USA 2003; 100: 7836-7840.
51. Xu J, Ahmad A, Jones JF, et al. Elevated serum transforming growth factor beta1 levels in Epstein-Barr virus-associated diseases and their correlation with virus-specific immunoglobulin A (IgA) and IgM. J Virol 2000; 74: 2443-2446.
52. Ohga S, Nomura A, Takada H, et al. Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. J Infect Dis 2001; 183: 1-7.
53. Ohga S, Nomura A, Takada H, Hara T. Immunological aspects of Epstein-Barr virus infection. Crit Rev Oncol Hematol 2002; 44: 203-215.
54. Lay JD, Tsao CJ, Chen JY, Kadin ME, Su IJ. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest 1997; 100: 1969-1979.
55. Roncella S, Cutrona G, Truini M, et al. Late Epstein-Barr virus infection of a hepatosplenic gamma delta T-cell lymphoma arising in a kidney transplant recipient. Haematologica 2000; 85: 256-262.
56. Shen L, Chiang AK, Liu WP, Li GD, Liang RH, Srivastava G. Expression of HLA class I, beta(2)-microglobulin, TAP1and IL-10 in Epstein-Barr virus-associated nasal NK/T-cell lymphoma: implications for tumor immune escape mechanism. Int J Cancer 2001; 92: 692-696.
57. Larche M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003; 111: 450-463.
58. Kapp U, Yeh WC, Patterson B, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999; 189: 1939-1946.
59. Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002; 100: 4059-4066.
60. Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998; 395: 462-469.
61. Purtilo DT, Cassel CK, Yang JP, Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1975; 1: 935-940.
62. Sumazaki R, Kanegane H, Osaki M, et al. SH2D1A mutations in Japanese males with severe Epstein-Barr virus-associated illnesses. Blood 2001; 98: 1268-1270.
63. Katano H, Ali MA, Patera AC, et al. Chronic active Epstein-Barr virus infection associated with mutations in perform that impair its maturation. Blood 2004; 103: 1244-1252.
64. Sneller MC, Straus SE, Jaffe ES, et al. A novel lymphoproliferative/ autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest 1992; 90: 334-341.
65. Wakiguchi H. Overview of Epstein-Barr virus-associated diseases in Japan. Crit Rev Oncol Hematol 2002; 44: 193-202.
66. Kawaguchi H, Miyashita T, Herbst H, et al. Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome. J Clin Invest 1993; 92: 1444-1450.
67. Kimura H, Tsuge I, Imai S, et al. Intact antigen presentation for Epstein-Barr virus (EBV)-specific CTL by a lymphoblastoid cell line established from a patient with severe chronic active EBV infection. Med Microbiol Immunol 1995; 184: 63-68.
68. Tsuge I, Morishima T, Kimura H, Kuzushima K, Matsuoka H. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection. J Med Virol 2001; 64: 141-148.
69. + T cells. Blood 2003; 101: 1460-1468.
70. + T cells in patients with chronic active EBV infection. J Infect Dis 2004; 190: 985-988.
71. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982; 306: 913-918.
72. Purtilo DT, Strobach RS, Okano M, Davis JR. Epstein-Barr virus-associated lymphoproliferative disorders. Lab Invest 1992; 67: 5-23.
73. Hoshino Y, Kimura H, Tanaka N, et al. Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation. Br J Haematol 2001; 115: 105-111.
74. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350: 1328-1337.
75. Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med 2002; 8: 594-599.
76. Tugizov SM, Berline JW, Palefsky JM. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med 2003; 9: 307-314.
77. Anagnostopoulos I, Hummel M, Kreschel C, Stein H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood 1995; 85: 744-750.
78. Hudnall SD, Ge Y, Wei L, Yang NP, Wang HQ, Chen T. Distribution and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils. Mod Pathol 2005; 18: 519-527.
79. Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 1984; 81: 4510-4514.
80. Fischer E, Delibrias C, Kazatchkine MD. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol 1991; 146: 865-869.
81. Yoshiyama H, Imai S, Shimizu N, Takada K. Epstein-Barr virus infection of human gastric carcinoma cells: implication of the existence of a new virus receptor different from CD21. J Virol 1997; 71: 5688-5691.
82. Molesworth SJ, Lake CM, Borza CM, Turk SM, Hutt-Fletcher LM. Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells. J Virol 2000; 74: 6324-6332.
83. Maruo S, Yang L, Takada K. Roles of Epstein-Barr virus glycoproteins gp350 and gp25 in the infection of human epithelial cells. J Gen Virol 2001; 82: 2373-2383.
84. Spriggs MK, Armitage RJ, Comeau MR, et al. The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation. J Virol 1996; 70: 5557-5563.
85. Li Q, Spriggs MK, Kovats S, et al. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol 1997; 71: 4657-4662.
86. Haan KM, Kwok WW, Longnecker R, Speck P. Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor. J Virol 2000; 74: 2451-2454.
87. Isobe Y, Sugimoto K, Yang L, et al. Epstein-Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells. Cancer Res 2004; 64: 2167-2174.
88. Tabiasco J, Vercellone A, Meggetto F, Hudrisier D, Brousset P, Fournie JJ. Acquisition of viral receptor by NK cells through immunological synapse. J Immunol 2003; 170: 5993-5998.
89. Kawa-Ha K, Franco E, Doi S, et al. Successful treatment of chronic active Epstein-Barr virus infection with recombinant interleukin-2. Lancet 1987; 1: 154. __
90. Ishida Y, Yokota Y, Tauchi H, et al. Ganciclovir for chronic active Epstein-Barr virus infection. Lancet 1993; 341: 560-561.
91. Sakai Y, Ohga S, Tonegawa Y, et al. Interferon-alpha therapy for chronic active Epstein-Barr virus infection: potential effect on the development of T-lymphoproliferative disease. J Pediatr Hematol Oncol 1998; 20: 342-346.
92. Kimura H, Morita M, Tsuge I, et al. Vidarabine therapy for severe chronic active Epstein-Barr virus infection. J Pediatr Hematol Oncol 2001; 23: 294-299.
93. Okamura T, Hatsukawa Y, Arai H, Inoue M, Kawa K. Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. Lancet 2000; 356: 223-224.
94. Fujii N, Takenaka K, Hiraki A, et al. Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection. Bone Marrow Transplant 2000; 26: 805-808.
95. Yagita M, Iwakura H, Kishimoto T, et al. Successful allogeneic stem cell transplantation from an unrelated donor for aggressive Epstein-Barr virus-associated clonal T-cell proliferation with hemophagocytosis. Int J Hematol 2001; 74: 451-454.
96. Uehara T, Nakaseko C, Hara S, et al. Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection. Am J Hematol 2004; 76: 368-372.
97. Ishihara S, Okada S, Wakiguchi H, Kurashige T, Morishima T, Kawa-Ha K. Chronic active Epstein-Barr virus infection in children in Japan. Acta Paediatrica 1995; 84: 1271-1275.
98. Kuzushima K, Yamamoto M, Kimura H, et al. Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol 1996; 103: 192-198.
99. Straathof KC, Bollard CM, Rooney CM, Heslop HE. Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist 2003; 8: 83-98.
100. Gottschalk S, Edwards OL, Sili U, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003; 101: 1905-1912.